[Experimental and clinical evaluation of latamoxef in pediatric surgery].
Latamoxef (LMOX), a new oxacephem antibiotic, was studied for assessment of fundamental and clinical efficacy in 6 patients with neonatal surgical diseases, and in 1 with congenital bile duct atresia. The results were obtained as follows: The serum levels of LMOX were 73.4--89.6 micrograms/ml at 15--30 minutes following 20 mg/kg intravenous one shot injection in postoperative neonatal surgical patients. The mean rate of urinary excretion was 29.1% for 6 hours following administration of LMOX. The biliary levels of LMOX were 5.52--10.2 micrograms/ml in maximum following 20 mg/kg intravenous one shot injection in a patient with congenital bile duct atresia, but the excretion rate in bile was poor from liver disfunction. Also, the negative correlationship was obtained between bile and urine excretion rate. LMOX was administered to 6 cases of neonatal surgical patients for prevention of the postoperative infection. The clinical results were good in 4, fair in 1 and not evaluated in 1 of these cases. No side effect was experienced.
D001646:Bile / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007275:Injections, Intravenous; D008297:Male; D009070:Moxalactam / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D011292:Premedication; D013530:Surgical Wound Infection / Q000188:drug therapy* / Q000517:prevention & control
D009070:Moxalactam